Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

Salvage radiation therapy (SRT) is recommended for men with biochemically recurrent prostate cancer post-radical prostatectomy. RTOG 9601 was a randomized phase 3 clinical trial that demonstrated an overall survival (OS) benefit from the addition of long-term anti-androgen therapy to SRT. However, hormone therapy has well documented side effects and has been shown to increase cardiac event rates, and there remains no evidence of an OS benefit from hormone therapy for men treated with early SRT. Herein, we aim to determine if pre-SRT PSA can serve as both a prognostic and predictive biomarker of benefit or harm from hormone therapy.

Source: International Journal of Radiation Oncology * Biology * Physics - September 18, 2019 Category: Radiology Authors: D.E. Spratt, R.T. Dess, J.A. Efstathiou, A.L. Zietman, D.G. Wallington, N.K. Jairath, W.C. Jackson, R.B. Den, B.J. Stish, T.M. Morgan, J.J. Dignam, T.M. Pisansky, S.A. Rosenthal, J.M. Michalski, O. Sartor, F.Y. Feng, M. Schipper, H.M. Sandler, Y. Sun, W.U Source Type: research